News & Research

STOXX Ltd., the operator of Deutsche Boerse Group’s index business, and a global provider of innovative and tradable index concepts, today announced that it has changed its Country Classification model.

Would you let a robot pick your investment portfolio? Deutsche Boerse AG’s STOXX Ltd. indexing business is set to find out with its two latest market gauges.

While we tend to think of artificial intelligence (AI) as the future, the truth is the technology has already transformed asset managers’ core business beyond recognition.

STOXX Ltd. introduced the world’s first index that uses AI-related algorithms to select companies exposed to the artificial intelligence (AI) megatrend at the Inside ETFs conference in the U.S. The new index will be available as of 23 January 2018.

As we reviewed the outlook for equity markets in 2018 in a recent article, UBS highlighted the disruptive trends of digitalization and robotics in its forecast, pointing out that technology stocks may continue their march higher.

In “An Aussie sense of style”, Axioma’s latest paper on smart beta products, we take a look at the inherent compromise between delivering target factor purity versus maximizing factor exposure.

After a bumper year for equities, strategists are forecasting further gains for 2018, while pointing to risks from rising bond yields and higher volatility.

The synchronized growth witnessed in 2017 is expected to continue this year, according to economists, who say markets can weather the gradual normalization of monetary policy.

Global stock indices extended their record-breaking rally in December to end 2017 with the biggest annual returns since 2013.

Despite the Fed’s and the ECB’s divergent trajectories, the dollar fell against the euro to $1.18 in December from $1.05 in January, confounding expectations. At the start of 2017, the average forecast from five banks pointed to the euro ending the year at $1.05.

The post-crisis economic recovery gathered pace in 2017 as the Eurozone and Japan joined the global growth momentum, helping investors push risk assets higher.

Whether it’s optimizers of patient treatment or hybrid bio-chemical drugs, many health-care stocks are inventing the future.